Summary
In 1992 patient accrual to the National Cancer Institute-sponsored Breast Cancer Prevention Trial was initiated in the United States and Canada. The Trial will involve 16,000 women who are evaluated to be at high risk of developing breast cancer. Nearly 250 health care organizations are participating in the Trial, including over 40 Community Clinical Oncology Program (CCOP) organizations*, which are a component of the NCI's national clinical trials program. A previous NCI-funded evaluation conducted by the University of North Carolina showed the CCOP program to be an effective means of transferring the latest cancer technology, particularly cancer treatments, to the community setting.
This paper describes a study designed to evaluate the performance of CCOP organizations in the Breast Cancer Prevention Trial. Using data from the first fifteen months of the Trial, the ability of CCOPs to accrue women is assessed using panel data estimation techniques. An attempt is made to predict accrual by structural, process, and environmental characteristics of participating CCOPs. Factors predictive of accrual include month in which accrual occurred and the extent of competition for trial participants in the CCOP service area. The hypothesized model explains slightly over 19 percent of the variation in accrual performance. The analysis demonstrates the utility of a panel data approach to modeling the dynamics of CCOP participation in a chemoprevention clinical trial.
Similar content being viewed by others
References
Love R: Antiestrogen chemoprevention of breast cancer: critical issues and research. Prev Med 20:64–78, 1991
Stone R: NIH fends off critics of tamoxifen study. Science 258:734, 1992
National Cancer Institute: Breast Cancer Prevention Trial press materials. Bethesda, MD, April 8, 1992
Kardinal C, Stuckey WJ, Bickers J: Clinical cancer research. J Louisiana State Med Assoc 143:27–29, 1991
Greenwald P, Cullen J, McKenna J: Cancer prevention and control: From research through applications. J Natl Cancer Inst 79:389–400, 1987
Kaluzny A, Ricketts T, Warnecke R, Ford L, Morrissey J, Gillings D, Sondik E, Ozer H, Goldman J: Evaluating organizational design to assure technology transfer: The case of the Community Clinical Oncology Program. J Natl Cancer Inst 81:1717–1725, 1989
Kaluzny A, Warnecke R, Lacey L, Johnson T: Assessment of the implementation and impact of the Community Clinical Oncology Program - Phase II -final report. Unpublished report, University of North Carolina at Chapel Hill, 1992
Kaluzny A, Lacey L, Warnecke R, Morrissey J, Sondik E, Ford L: Accrual to randomized clinical trials: Factors affecting cancer prevention and control research. Int J Technology Assessment in Health Care 10:506–516, 1994
Kaluzny A, Lacey L, Warnecke R, Hynes D, Morrissey J, Ford L, Sondik E: Predicting the performance of a strategic alliance: An analysis of the Community Clinical Oncology Program. Health Serv Res 28(2): 159–182, 1993
Matyas L, Sevestre P: The Econometrics of Panel Data: Handbook of Theory and Applications. Kluwer, Boston, 1992.
Sayrs LW: Pooled Time Series Analysis. Sage Publ, Newbury Park CA, 1989.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klabunde, C.N., Kaluzny, A.D. Accrual to the Breast Cancer Prevention Trial by participating Community Clinical Oncology Programs: A panel data analysis. Breast Cancer Res Tr 35, 43–50 (1995). https://doi.org/10.1007/BF00694744
Issue Date:
DOI: https://doi.org/10.1007/BF00694744